Allogeneic hematopoietic cell transplantation using fludarabine plus myeloablative busulfan and melphalan confers promising survival in high-risk hematopoietic neoplasms: a single-center retrospective analysis

References

• Gyurkocza B, Sadmaier BM. Conditioning regimens for hematopoietic cell transplantation: one size does not fit all. Blood. 2014;124(3):344–353. doi:https://doi.org/10.1183/blood-2014-02-514778.
   PubMed Web of Science ®Google Scholar
• Jain T, Alahdab F, Firwana B, et al. Choosing a reduced-intensity conditioning regimen for allogeneic stem cell transplantation, fludarabine/busulfan versus fludarabine melphalan: a systematic review and meta-analysis. Biol Blood Marrow Transplant. 2019;25(4):728–733. doi:https://doi.org/10.1016/j.bbmt.2018.11.016.
   PubMed Web of Science ®Google Scholar
• Abdul Wahid SF, Ismail NA, Mohd-Idris MR, et al. Comparison of reduced-intensity and myeloablative conditioning regimens for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia and acute lymphoblastic leukemia: a meta-analysis. Stem Cells Dev. 2014;23(21):2535–2552. doi:https://doi.org/10.1089/scd.2014.0123.
   PubMed Web of Science ®Google Scholar
• Nagler A, Rocha V, Labopin M, et al. Allogeneic hematopoietic stem-cell transplantation for acute myeloid leukemia in remission: comparison of intravenous busulfan plus cyclophosphamide (Cy) versus total-body irradiation plus Cy as conditioning regimen–a report from the acute Leukemia working party of the European Group for blood and marrow transplantation. J Clin Oncol. 2013;31(28):3549–3556. doi:https://doi.org/10.1200/JCO.2013.48.8114.
   PubMed Web of Science ®Google Scholar
• Copelan EA, Hamilton BK, Avalos B, et al. Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI. Blood. 2013;122(24):3863–3870. doi:https://doi.org/10.1182/blood-2013-07-514448.
   PubMed Web of Science ®Google Scholar
• Bredeson C, LeRademacher J, Kato K, et al. Prospective cohort study comparing intravenous busulfan to total body irradiation in hematopoietic cell transplantation. Blood. 2013;122(24):3871–3878. doi:https://doi.org/10.1182/blood-2013-08-519009.
   PubMed Web of Science ®Google Scholar
• Mitsuhashi K, Kako S, Shigematsu A, et al. Comparison of cyclophosphamide combined with total body irradiation, oral busulfan, or intravenous busulfan for allogeneic hematopoietic cell transplantation in adults with acute lymphoblastic leukemia. Biol Blood Marrow Transplant. 2016;22(12):2194–2200. doi:https://doi.org/10.1016/j.bbmt.2016.09.007.
   PubMed Web of Science ®Google Scholar
• Kebriaei P, Anasetti C, Zhang MJ, et al. Intravenous busulfan compared with total body irradiation pretransplant conditioning for adults with acute lymphoblastic leukemia. Biol Blood Marrow Transplant. 2018;24(4):726–733. doi:https://doi.org/10.1016/j.bbmt.2017.11.025.
   PubMed Web of Science ®Google Scholar
• Rodriguez R, Nademanee A, Ruel N, et al. Comparison of reduced-intensity and conventional myeloablative regimens for allogeneic transplantation in non-Hodgkin’s lymphoma. Biol Blood Marrow Transplant. 2006;12(12):1326–1334. doi:https://doi.org/10.1016/j.bbmt.2006.08.035.
   PubMed Web of Science ®Google Scholar
• Shimoni A, Nagler A. Optimizing the conditioning regimen for allogeneic stem-cell transplantation in acute myeloid leukemia; dose intensity is still in need. Best Pract Res Clin Haematol. 2011;24(3):369–379. doi:https://doi.org/10.1016/j.beha.2011.05.002.
   PubMedGoogle Scholar
• Veltri L, Rezvani K, Oran B, et al. Allotransplants for patients 65 years or older with high-risk acute myeloid leukemia. Biol Blood Marrow Transplant. 2019;25(3):505–514. doi:https://doi.org/10.1016/j.bbmt.2018.09.032.
   PubMedGoogle Scholar
• Gooptu M, Kim HT, Ho VT, et al. A comparison of the myeloablative conditioning regimen fludarabine/busulfan with cyclophosphamide/total body irradiation for allogeneic stem cell transplantation in the modern era: a cohort analysis. Biol Blood Marrow Transplant. 2018;24(8):1733–1740. doi:https://doi.org/10.1016/j.bbmt.2018.03.011.
   PubMed Web of Science ®Google Scholar
• Fedele R, Messina G, Martinello T, et al. Tolerability and efficacy of busulfan and fludarabine as allogeneic pretransplant conditioning therapy in acute myeloid leukemia: comparison with busulfan and cyclophosphamide regimen. Clin Lymphoma Myeloma Leukemia. 2014;14(6):493–500. doi:https://doi.org/10.1016/j.clml.2014.04.006.
   PubMedGoogle Scholar
• Harris AC, Boelens JJ, Ahn KW, et al. Comparison of pediatric allogeneic transplant outcomes using myeloablative busulfan with cyclophosphamide or fludarabine. Blood Adv. 2018;2(11):1198–1206. doi:https://doi.org/10.1182/bloodadvances.2018016956.
   PubMedGoogle Scholar
• Horowitz ME, Morris A, Gasparetto C, et al. Myeloablative intravenous busulfan/fludarabine conditioning does not facilitate reliable engraftment of dual umbilical cord blood grafts in adult recipients. Biol Blood Marrow Transplant. 2008;14(5):591–594. doi:https://doi.org/10.1016/j.bbmt.2008.02.0116.
   PubMedGoogle Scholar
• Yamamoto H, Uchida N, Yuasa M, et al. A novel reduced-toxicity myeloablative conditioning regimen using full-dose busulfan, fludarabine, and melphalan for single cord blood transplantation provides durable engraftment and remission in nonremission myeloid malignancies. Biol Blood Marrow Transplant. 2016;22(10):1844–1850. doi:https://doi.org/10.1016/j.bbmt.2016.06.017.
   PubMed Web of Science ®Google Scholar
• Katsanis E, Sapp LN, Pelayo-Katsanis L, et al. Alternative donor hematopoietic cell transplantation conditioned with myeloablative busulfan, fludarabine, and melphalan is well tolerated and effective against high-risk myeloid malignancies. J Pediatr Hematol Oncol. 2016;38(8):e315–e318. doi:https://doi.org/10.1097/MPH.0000000000000621.
   PubMedGoogle Scholar
• Ueda T, Maeda T, Kusakabe S, et al. Addition of melphalan to fludarabine/busulfan (FLU/BU4/MEL) provides survival benefit for patients with myeloid malignancy following allogeneic bone-marrow transplantation/peripheral blood stem-cell transplantation. Int J Hematol. 2019;109(2):197–205. doi:https://doi.org/10.1007/s12185-018-2562-8.
   PubMedGoogle Scholar
• Ueda T, Jo T, Okada K, et al. Curative potential of fludarabine, melphalan, and non-myeloablative dosage of busulfan in elderly patients with myeloid malignancy. Int J Hematol. 2020;111(2):247–255. doi:https://doi.org/10.1007/s12185-019-02763-2.
   PubMedGoogle Scholar
• Przepiorka D, Weisdorf D, Martin P, et al. 1994 consensus conference on acute GVHD grading. Bone Marrow Transplant. 1995;15(6):825–828.
   PubMed Web of Science ®Google Scholar
• Jagasia MH, Greinix HT, Arora M, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 diagnosis and staging Working Group report. Biol Blood Marrow Transplant. 2015;21(3):389–401.e1. doi:https://doi.org/10.1016/j.bbmt.2014.12.001.
   PubMed Web of Science ®Google Scholar
• Mohty M, Malard F, Abecassis M, et al. Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a new classification from the European Society for blood and marrow transplantation. Bone Marrow Transplant. 2016;51(7):906–912. doi:https://doi.org/10.1038/bmt.2016.130.
   PubMed Web of Science ®Google Scholar
• Ruutu T, Barosi G, Benjamin RJ, et al. Diagnostic criteria for hematopoietic stem cell transplant-associated microangiopathy: results of a consensus process by an International Working Group. Haematologica. 2007;92(1):95–100.
   PubMed Web of Science ®Google Scholar
• Armand P, Kim HT, Logan BR, et al. Validation and refinement of the disease risk index for allogeneic stem cell transplantation. Blood. 2014;123(23):3664–3671. doi:https://doi.org/10.1182/blood-2014-01-552984.
   PubMed Web of Science ®Google Scholar
• Kanda J, Ichinohe T, Saito T, et al. Impact of discontinuing fluoroquinolone prophylaxis on early mortality after allogeneic marrow or peripheral blood SCT with myeloablative conditioning. Bone Marrow Transplant. 2010;45(8):1369–1371.
   PubMed Web of Science ®Google Scholar
• Yakushijin K, Ikezoe T, Ohwada C, et al. Clinical effects of recombinant thrombomodulin and defibrotide on sinusoidal obstruction syndrome after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2019;54(5):674–680. doi:https://doi.org/10.1038/s41409-018-0304-4.
   PubMedGoogle Scholar
• Yabe M, Sako M, Yabe H, et al. A conditioning regimen of busulfan, fludarabine, and melphalan for allogeneic stem cell transplantation in children with juvenile myelomonocytic leukemia. Pediatr Transplant. 2008;12(8):862–867. doi:https://doi.org/10.1111/j.1399-3046.2008.00931.x.
   PubMed Web of Science ®Google Scholar
• Yabe M, Ohtsuka Y, Watanabe K, et al. Transplantation for juvenile myelomonocytic leukemia: a retrospective study of 30 children treated with a regimen of busulfan, fludarabine, and melphalan. Int J Hematol. 2015;101(2):184–190. doi:https://doi.org/10.1007/s12185-014-1715-7.
   PubMed Web of Science ®Google Scholar
• Shimoni A, Hardan I, Shem-Tov N, et al. Comparison between two fludarabine-based reduced-intensity conditioning regimens before allogeneic hematopoietic stem-cell transplantation: fludarabine/ melphalan is associated with higher incidence of acute graft-versus-host disease and non-relapse mortality and lower incidence of relapse than fludarabine/busulfan. Leukemia. 2007;21(10):2109–2116.
   PubMed Web of Science ®Google Scholar
• Damlaj M, Alkhateeb HB, Hefazi M, et al. Fludarabine-busulfan reduced-intensity conditioning in comparison with fludarabine-melphalan is associated with increased relapse risk in spite of pharmacokinetic dosing. Biol Blood Marrow Transplant. 2016;22(8):1431–1439. doi:https://doi.org/10.1016/j.bbmt.2016.04.026.
   PubMed Web of Science ®Google Scholar
• Kawamura K, Kako S, Mizuta S, et al. Comparison of conditioning with fludarabine/busulfan and fludarabine/melphalan in allogeneic transplantation recipients 50 years or older. Biol Blood Marrow Transplant. 2017;23(12):2079–2087. doi:https://doi.org/10.1016/j.bbmt.2017.09.003.
   PubMed Web of Science ®Google Scholar
• Jain T, Kunze KL, Temkit M, et al. Comparison of reduced intensity conditioning regimens used in patients undergoing hematopoietic stem cell transplantation for myelofibrosis. Bone Marrow Transplant. 2019;54(2):204–211. doi:https://doi.org/10.1038/s41409-018-0226-1.
   PubMed Web of Science ®Google Scholar
• Oshrine B, Adams L, Nguyen ATH, et al. Comparison of melphalan- and busulfan-based myeloablative conditioning in children undergoing allogeneic transplantation for acute myeloid leukemia or myelodysplasia. Pediatr Transplant. 2020;24:e13672. doi:https://doi.org/10.1111/petr.13672.
   PubMedGoogle Scholar
• Gorin NC, Labopin M, Blaise D, et al. Optimizing the pretransplant regimen for autologous stem cell transplantation in acute myelogenous leukemia: better outcomes with busulfan and melphalan compared with busulfan and cyclophosphamide in high risk patients autografted in first complete remission: A study from the acute leukemia working party of the EBMT. Am J Hematol. 2018;93(7):859–866. doi:https://doi.org/10.1002/ajh.25105.
   PubMedGoogle Scholar
• Jaiswal SR, Chakrabarti A, Chatterjee S, et al. Haploidentical peripheral blood stem cell transplantation with post-transplantation cyclophosphamide in children with advanced acute leukemia with fludarabine-, busulfan-, and melphalan-based conditioning. Biol Blood Marrow Transplant. 2016;22(3):499–504. doi:https://doi.org/10.1016/j.bbmt.2015.11.010.
   PubMedGoogle Scholar
• Cornillon J, Daguenet E, Bay JO, et al. BAM conditioning before autologous transplantation for lymphoma: a study on behalf of the Francophone society of bone marrow transplantation and cellular therapy (SFGM-TC). Ann Hematol. 2019;98(8):1973–1980. doi:https://doi.org/10.1007/s00277-019-03704-z.
   PubMedGoogle Scholar
• Bashir Q, Thall PF, Milton DR, et al. Conditioning with busulfan plus melphalan versus melphalan alone before autologous haemopoietic cell transplantation for multiple myeloma: an open-label, randomised, phase 3 trial. Lancet Haematol. 2019;6(5):e266–e275. doi:https://doi.org/10.1016/S2352-3026(19)30023-7.
   PubMed Web of Science ®Google Scholar
• Kebriaei P, Madden T, Wang X, et al. Intravenous BU plus Mel: an effective, chemotherapy-only transplant conditioning regimen in patients with ALL. Bone Marrow Transplant. 2013;48(1):26–31. doi:https://doi.org/10.1038/bmt.2012.114.
   PubMedGoogle Scholar
• MacKay M, Afshinnekoo E, Rub J, et al. The therapeutic landscape for cells engineered with chimeric antigen receptors. Nat Biotechnol. 2020;38(2):233–244. doi. https://doi.org/10.1038/s41587-019-0329-2.
   PubMed Web of Science ®Google Scholar